WOBURN, Mass.--(BUSINESS WIRE)--BioTrove, Inc. today announced the release of a fully-validated suite of twelve cytochrome P450 inhibition assays for performing drug-drug interaction (DDI) assays on the RapidFire Mass Spectrometry platform (RF-MS). With throughputs approaching fluorescence- or radioactivity-based methods (3500 data points per eight-hour shift on a single instrument), and full compatibility with liver microsome preparations, the RapidFire P450 inhibition assay platform enables researchers to advance lead optimization with highly accurate mass spectrometric data.
